Monoclonal antibodies (mAbs) aid the body against autoimmune diseases and cancer, among other things. Patients have to pick ...

A research team at Tohoku University, in collaboration with Denka Company Limited and U-A Corporation, has developed a ...

The MarketWatch News Department was not involved in the creation of this content. PHILADELPHIA, Dec. 17, 2025 (GLOBE NEWSWIRE) -- The U.S. Judicial Panel on Multidistrict Litigation has ordered the ...

PHILADELPHIA, Dec. 17, 2025 (GLOBE NEWSWIRE) -- The U.S. Judicial Panel on Multidistrict Litigation has ordered the creation of a new federal multidistrict litigation consolidating lawsuits alleging ...

DEC 15 (Reuters) - A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly alleging patients lost some or all of their eyesight while ...

ScriptView Flip can be printed through ScriptAbility Software, which creates accessible prescription labels and features RxCode, a QR code that gives patients additional access to label and ...

The healthcare industry faces major challenges in creating new drugs that can improve outcomes in the treatment of all kinds of diseases. New generative AI models could play a major role in breaking ...

FRANKLIN, Ind. — When Elizabeth Wilde Gestner woke up one morning in September 2024, something wasn’t right. She could not see out of most of her right eye. There was no warning. No physical pain.

What Is Eylea HD, and Why Does It Matter? Eylea HD (aflibercept) is an injectable medicine used to treat certain eye conditions that can lead to vision loss. It works by blocking a protein called VEGF ...

COPENHAGEN, Nov 21 (Reuters) - Four patients in Denmark, who experienced vision loss after using Novo Nordisk's (NOVOb.CO), opens new tab popular weight-loss and diabetes drugs Wegovy and Ozempic, ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Contineum Therapeutics’ M1 receptor antagonist has failed to move the needle in a phase 2 vision test for patients with a common form of multiple sclerosis. The Johnson & Johnson-partnered asset, ...